Something unusual happened on June 18th. The FDA’s top vaccine advisory committee voted 9-0 to recommend Moderna’s mRNA flu shot for adults 50 and older. Not 7-2, not 6-3. A clean sweep. That kind of unanimous result is rare in biotech. And the market, after years of treating Moderna like a one-product COVID casualty, is paying attention in a serious way.

MRNA is up over 117% year to date. As of June 26th, the stock hit a new 52-week high of $69.29 intraday, up roughly 14% on the day alone. That’s not a rumor. It’s the actual number, and it happened while most of the vaccine space stayed flat or fell.

Here’s the thing: most of that move isn’t about one day’s euphoria. It’s about a fundamental story that’s been rebuilding for months. The COVID hangover is still real. Q1 2026 revenue came in at $389 million, up 264% year over year, but the company posted a GAAP EPS loss of $3.40. That number looks worse than it is, though. It includes a $0.9 billion one-time litigation settlement charge. Strip that out, and the underlying quarter actually beat analyst expectations by a wide margin. The losses are large. Nobody’s pretending otherwise. What’s changed is the path forward.

The mFlusiva flu vaccine (mRNA-1010) just became the most de-risked asset in Moderna’s portfolio. The FDA has set an August 5 PDUFA date. The agency isn’t bound by advisory committee recommendations, but it follows them the overwhelming majority of the time. A 9-0 unanimous vote doesn’t leave much ambiguity. Moderna is seeking standard approval for the 50-64 age group and accelerated approval for adults 65 and older, which would require a postmarketing trial of up to 800,000 participants, but both paths lead to the same commercial destination.

Worth flagging: this product had a genuinely rocky road to get here. In February 2026, the FDA issued a Refusal to File letter, with CBER director Vinay Prasad citing concerns about the comparator used in the older adult study. Days later, the FDA reversed course. Prasad departed in April. The June 18 advisory meeting followed, and the vote was as clean as it gets.

Slight tangent, but it matters: the political backdrop is genuinely complicated. The ACIP, which is the CDC committee that determines vaccine coverage recommendations, remains in a disputed position, and HHS Secretary Robert F. Kennedy Jr. has publicly questioned whether the panel can carry out its core responsibilities. Without an ACIP recommendation, insurance coverage for mFlusiva could be delayed even after FDA approval. That’s not a dealbreaker. It is a wildcard that the market hasn’t fully absorbed yet.

Wall Street is split in a way that’s actually informative. Jefferies raised its price target to $53 from $45 after Science Day while keeping a Hold rating, still arguing that meaningful flu revenues don’t realistically start until around 2027. BofA sits at $34 with an Underperform. Leerink is near $24. Morgan Stanley near $33. The consensus analyst target is around $43, well below where the stock is trading right now. On the other end, Morningstar has a fair value of $98. The range of targets spans from the low $20s to nearly $70. That’s not confusion. That’s genuine disagreement about the timeline, and about whether the market is pricing 2027 revenue or 2030 revenue.

The Science Day on June 25th showed a company building three commercial franchises: respiratory vaccines, oncology therapeutics, and rare diseases. Jefferies noted that by 2027-28, Moderna could be marketing seven or more products across those areas. Right now it has three on the market: Spikevax, mNEXSPIKE, and mRESVIA. The oncology angle is further out. Intismeran, Moderna’s personalized cancer vaccine built with Merck, has Phase 3 data in melanoma expected later this year. In-vivo CAR-T and T-cell engager programs are earlier stage. But management’s message is clear: 2026 is the inflection year, 2027 and 2028 are when multiple launches converge.

The EU-approved flu-COVID combo vaccine, mCOMBRIAX, is already on shelves in Europe as of April 2026. A single shot covering both flu and COVID in one dose is a fundamentally different commercial product than anything else in the respiratory vaccine market. U.S. approval is a separate regulatory path, and Moderna pulled its FDA application in May 2025, saying a resubmission depends on further data from mFlusiva. But a successful August 5 approval could unlock that path. The European launch gives Moderna real-world rollout experience in the meantime.

For anyone watching the August 5 date, implied volatility in MRNA options has been elevated heading into the decision. Even an approval might prompt a sell-the-news reaction in a stock that’s already more than doubled year to date. Approval is increasingly the base case. The question is what that approval is actually worth in 2026 versus what it’s worth in 2028 when the revenue model fills out.

Jefferies at $53 and BofA at $34 while the stock trades near $68 tells you everything about where the debate sits. Either the bears are right and this rally corrects hard once the August catalyst passes, or the bull case starts getting modeled into consensus: three commercial products, seven by 2028, flu revenues scaling to $750 million or more in U.S. and combo sales. Neither outcome is boring.

The part worth watching isn’t the August 5 decision itself. It’s what happens to ACIP, how fast insurance coverage actually comes through, and whether the severity of the 2024-25 flu season (the CDC confirmed at least 43 million illnesses, 560,000 hospitalizations, and 38,000 deaths, making it the most severe season since 2017-18) actually drives demand for a better vaccine when one finally exists.

That’s a much harder question than whether the FDA approves mFlusiva. And the answer isn’t on any PDUFA calendar.